Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo

Wells Fargo analyst Derek Archila raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $145 from $129 and keeps an Overweight rating on the shares. The firm says IMCIVREE’s Q4 revenue beat was a positive surprise. Its IMCIVREE revenue estimates largely remain unchanged for FY26 though it pushes its modest Q1 hypothalamic obesity sales due to the PDUFA extension. However, based on Wells’ management dinner, it is now incorporating Prader-Willi syndrome into its model at a 35% probability of success.